The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

For reference, Novo Nordisk also offers a highly successful weight loss drug, Wegovy, a GLP-1 receptor agonist.

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.